Clinical trial NCT02641899: Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs
Official title: A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Adult
Male
Female
Volunteers
Lead sponsor: Intarcia Therapeutics
Sponsor class: INDUSTRY
First posted: 2015-12-30
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied DDI Probe Compounds.

Detailed description: Acetaminophen will be use to assess the effect of ITCA 650 on the rate of gastric emptying.

Interactions between ITCA 650 and the medications lisinopril, digoxin, atorvastatin, and warfarin will also be studied.

Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) between 19 to 32 kg/m2.
* Glycosylated hemoglobin A1c (HbA1c )\<6.5%.
* Normal renal function (eGFR ≥80 mL/min/1.73 m2).
* Women of child bearing potential - use of an additional adequate method of contraception during the study and until 1 additional menstrual cycle following the end-of-study (EOS) visit. Adequate methods of contraception for women of child bearing potential (WOCBP) include: mechanical products (ie, intrauterine device \[IUD\]-copper IUD); or barrier methods (eg, diaphragm, condoms, cervical cap) with spermicide.

Exclusion Criteria:

* History of type 1 or type 2 diabetes.
* History or evidence of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke.
* History of uncontrolled hypertension.
* History or evidence of acute or chronic pancreatitis.
* History of liver disease.
* History of medullary thyroid cancer or a personal or family history of multiple endocrine neoplasia type 2.
* Poor thyroid, liver, or renal function.
* Weight loss surgery or requires weight loss medications.
* History of malignancy (not including basal or squamous cell carcinoma of the skin with past 5 years). (Subjects who have been disease free for 5 years may be included.)
* History of active alcohol or substance abuse.
* Weekly consumption of more than 7 alcoholic beverages for females and 14 alcoholic beverages for males.
* Excessive in xanthine consumption (more than 5 cups of coffee or equivalent per day).
* Treatment with medications that affect GI motility.
* Any condition that would affect drug transit time or absorption (eg, gastrointestinal bypass surgery, partial or total gastrectomy, small bowel resection, chronic diarrhea, vagotomy, chronic gastroesophageal reflux disease, malabsorption, colostomy, Crohn's disease, ulcerative colitis, or celiac sprue).
* History of hypersensitivity to exenatide.
* Contraindications or warnings according to the specific label(s) for acetaminophen, atorvastatin, lisinopril, digoxin or warfarin therapy.
* Women that are pregnant, lactating, or planning to become pregnant.
* Concurrent use of anticoagulants, including daily low dose aspirin (81 mg).
* History of or positive results on screening tests for hepatitis B and/or hepatitis C and/or human immunodeficiency virus (HIV).
* Planned in-patient surgery, dental procedure, or hospitalization during the study.
* Prior or current treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (eg, Bydureon™, Byetta®, Victoza®, Tanzeum® or exogenous native GLP-1) or prior participation in an ITCA 650 clinical trial.
* Use or intended use of any drug or other product that inhibits or induces cytochrome P450 (CYP)1A2, CYP2C9, CYP2C19, or CYP3A4 within 14 days prior to the first dose of warfarin or ITCA650 or during the conduct of the study.
* History of thrombophlebitis, thromboembolic disorders, or deep vein thrombophlebitis.
* Fasting triglycerides above upper limit of normal at Screening.
* Any gastrointestinal complaints within 7 days prior to first dosing.
* Taking drugs or natural herbal supplements (such as albuterol, antacids, and St. John's Wort) with known interactions with atorvastatin, lisinopril, digoxin, or warfarin from within 7 days prior to Day 1 until EOS
* Consumed or unwilling to refrain from grapefruit, cranberries, grapefruit- or cranberry-containing products, or Seville oranges from within 7 days prior to Day 1 until EOS.
* Chronic use of analgesics, pain medication, or non-steroidal anti-inflammatory agents.

Primary outcomes:
measure: Area under the concentration-time curve from time zero to the last measurable concentration [AUC(0-last)]) of acetaminophen alone and in the presence of ITCA 650.
timeFrame: time zero to 10 weeks
measure: Maximum plasma concentration ([Cmax]) of acetaminophen alone and in the presence of ITCA 650
timeFrame: time zero to 10 weeks
measure: Area under the concentration-time curve (AUC(0-last)) of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650.
timeFrame: time zero to 10 weeks
measure: Cmax of atorvastatin, lisinopril, digoxin, R-warfarin, and S-warfarin each alone and in the presence of ITCA 650.
timeFrame: time zero to 10 weeks
Secondary outcomes:
measure: Time to maximum plasma concentration (tmax) of acetaminophen
timeFrame: time zero to 10 weeks
measure: tmax of atorvastatin, lisinopril, digoxin, R warfarin, and S-warfarin
timeFrame: time zero to 10 weeks
measure: AUC(0-last) of orthohydroxy-atorvastatin and parahydroxy-atorvastatin
timeFrame: time zero to 10 weeks
measure: Cmax of orthohydroxy-atorvastatin and parahydroxy-atorvastatin
timeFrame: time zero to 10 weeks
measure: Maximum effect (Emax)from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.
timeFrame: time zero to 10 weeks
measure: Cmax of ITCA 650, 20 mcg/d and 60 mcg/d
timeFrame: within 8 hours after placement of ITCA 650
measure: Treatment-emergent adverse events (TEAEs) including any events local to the placement site, clinical laboratory measurements, ECGs, vital signs and physical examinations.
timeFrame: time zero to 10 weeks
measure: Tmax of orthohydroxy-atorvastatin and parahydroxy-atorvastatin
timeFrame: time zero to 10 weeks
measure: Cmin of ITCA 650, 20 mcg/d and 60 mcg/d
timeFrame: time zero to 10 weeks
measure: Tmax of ITCA 650, 20 mcg/d and 60 mcg/d
timeFrame: time zero to 10 weeks
measure: Tmin of ITCA 650, 20 mcg/d and 60 mcg/d
timeFrame: zero to 10 weeks
measure: Time of maximum effect (tEmax)from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.
timeFrame: zero to 10 weeks
measure: Area under the effect-time curve from time zero to the last measurable concentration (AUEC(0-last)) of international normalized ratio (INR) of warfarin.
timeFrame: zero to 10 weeks
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Quintiles
state: Kansas
Study officials:
References: